Recently disclosed financial records have revealed that the cost of making and releasing Sam Raimi’s “Doctor Strange in the Multiverse of Madness” at Marvel Studios surged to a staggering $414.9 million in total according to Forbes.
That makes it one of the most expensive instalments in the Marvel Cinematic Universe, and surpassed “Avengers: Age of Ultron” which cost a total of $388.3 million but ended up grossing considerably more. Other recent Marvel films cost notably less including “Ant-Man and the Wasp Quantumania” at $328.2 million and “The Marvels” at $277.3 million – that’s all prior to any reimbursement.
Films shot in the United Kingdom benefit from the government’s Audio-Visual Expenditure Credit offering a cash reimbursement of up to 25.5% of money spent in the country – to qualify, films must pass a points test based on various factors.
To receive the reimbursement, at least 10% of a film’s core production costs need to relate to activities in the UK so studios set up a separate Film Production Company in the UK for each picture they make there which handles all costs related to it. Said companies also have to file publicly-available financial statements.
The production reportedly scored a $64.3 million reimbursement from the UK government, thus reducing Disney’s net spending on the movie down to $350.6 million.
‘Multiverse of Madness’ pulled in $955.8 million at the box-office, the highest-grossing Marvel movie since the start of the pandemic, which presumably means Disney’s share comes to half of that figure at $477.9 million (the other half going to exhibitors).
Minus the $350.6 million negative cost, it leaves Disney with $127.3 million profit at the box office which is reportedly more than any other UK-based MCU movie has made since the start of the pandemic.
Marvel’s most expensive films to date remain “Avengers: Infinity War” and “Avengers: Endgame” which the outlet claims came to a combined total cost of $1.265 billion.
The post “Doctor Strange” Sequel Cost $415M? appeared first on Dark Horizons.